ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Investing Cash Flow history
Currency unavailable · from the cash flow
No Investing Cash Flow data reported for this period type.
Investing Cash Flow vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $149.75M USD | +44.2% | +59.7% | 466.8% | |
| LTM Mar 2026 | $17.63M USD | -130.5% | +32.2% | 437.0% | |
| LTM Mar 2026 | $6.39M USD | — | +32.8% | 693.3% | |
| LTM Mar 2026 | $4.66M USD | -16.4% | -55.0% | 5.8% | |
| FY2025 | $1.45M USD | — | — | 7.8% | |
| LTM Mar 2026 | $981.99K USD | +43.1% | -17.0% | 1.4% | |
| LTM Mar 2026 | €955.79K EUR | -107.1% | +11.8% | 7.1% | |
| LTM Mar 2026 | $59.66K USD | -89.1% | -69.0% | 0.1% | |
| LTM Mar 2026 | $27.51K USD | +48.2% | +11.5% | — | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -16.4% | +11.6% | 7.4% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.